Wood S F
Clin Allergy. 1986 May;16(3):195-201. doi: 10.1111/j.1365-2222.1986.tb00766.x.
Seventy-four patients with a well documented history of seasonal allergic rhinitis were randomly allocated to receive either astemizole 10 mg orally per day or beclomethasone 100 micrograms in each nostril twice daily on a double-blind double-dummy basis. The patients were studied in a general practice setting and were seen at entry, during the study and at the end of the study by a single observer, the author. Assessment was by diary card incorporating five 10 cm visual analogue scales related to the four symptoms of sneezing, rhinorrhoea, blocked nose and itchy eyes and an overall assessment of hay fever symptoms. Patients were asked if the medication had upset them in any way at each observer assessment. Symptom severity, as recorded by the visual analogue scales, was not significantly different for sneezing, rhinorrhoea, blocked nose or overall between the two groups but the symptom scores for itchy eyes were significantly better for the astemizole group. Adverse effects were minimal and of a minor nature only. There was no real difference between the two groups regarding adverse effects. The study suggests that oral astemizole is at least as good as nasal beclomethasone in the maintenance treatment of hay fever and that it offers the additional advantage of improved control of eye symptoms.
74例有充分记录的季节性变应性鼻炎患者被随机分配,在双盲双模拟的基础上,每日口服10mg阿司咪唑或每侧鼻孔每日两次各喷入100μg倍氯米松。患者在普通诊所接受研究,由第一作者(即唯一的观察者)在入组时、研究期间和研究结束时进行观察。通过日记卡进行评估,日记卡包含5个10cm的视觉模拟量表,分别与打喷嚏、流涕、鼻塞和眼痒这4种症状以及花粉症症状的总体评估相关。在每次观察者评估时,询问患者药物是否对他们有任何不适影响。根据视觉模拟量表记录的症状严重程度,两组在打喷嚏、流涕、鼻塞或总体症状方面无显著差异,但阿司咪唑组的眼痒症状评分明显更好。不良反应轻微且仅为轻度。两组在不良反应方面无实际差异。该研究表明,口服阿司咪唑在花粉症维持治疗中至少与鼻用倍氯米松一样有效,并且它还具有更好地控制眼部症状的额外优势。